Clinical Trials and Research - The company completed patient recruitment for the Phase II clinical trial of IMM01 combined with Azacitidine for high-risk Myelodysplastic Syndromes (MDS) patients, achieving an overall response rate (ORR) of 64.7% with a complete response (CR) rate of 33.3%[5] - For the Phase II trial of IMM01 combined with Azacitidine in Chronic Myelomonocytic Leukemia (CMML), the ORR reached 72.7%, with a median progression-free survival (PFS) of 17.8 months[5] - The company received IND approval for the Phase III clinical trial of IMM01 combined with Azacitidine for CMML treatment, with 104 subjects recruited by December 31, 2025[5] - The company reported a total of 183 patients recruited for the Phase Ib/II trial of IMM2510, with an ORR of 35.3% in advanced squamous non-small cell lung cancer (SQ-NSCLC) patients[7] - The company initiated a Phase II study of IMM2510 combined with chemotherapy for NSCLC, with 69 evaluable patients as of December 31, 2025[8] - The company completed patient recruitment for the Phase I trial of IMM0306 combined with Lenalidomide in relapsed/refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL), demonstrating good tolerability[9] - The median follow-up time for the IMM01 trial in CMML was 21.0 months, with a 12-month PFS rate of 59.0%[5] - The company achieved a median duration of response (DoR) of 21.2 months in the Phase II trial for classical Hodgkin lymphoma (cHL) patients[7] - The overall response rate (ORR) for the combination treatment of Amurivimab α and Lenalidomide in relapsed or refractory CD20-positive follicular lymphoma was 91.2% (31/34), with a complete response (CR) rate of 67.6% (23/34) and a median progression-free survival (PFS) of 9.02 months[11] - In the systemic lupus erythematosus (SLE) Ib trial, the SRI-4 remission rates at week 24 were 71.4% (5/7) for the 0.8 mg/kg dose group and 80% (4/5) for the 1.2 mg/kg dose group[12] - The company received IND approval for the Phase II trial of lupus nephritis (LN) in December 2024 and for IgG4-related disease (IgG4-RD) in February 2026[14] - The company has initiated the first patient dosing in the Phase Ib trial for neuromyelitis optica spectrum disorder (NMOSD) in December 2024[12] - The company has a robust pipeline with over ten innovative drug candidates and twelve ongoing clinical projects[17] - The company is focused on developing innovative tumor immunotherapies and has a deep understanding of cutting-edge tumor biology and immunology[17] - The core product IMM01, an innovative CD47-targeting molecule, is the first SIRPα-Fc fusion protein to enter clinical stages in China[21] - The Phase III study (IMM01-009) for newly diagnosed high-risk MDS patients was approved in May 2024, with a median follow-up time of 21.0 months showing an ORR of 72.7%[24] - The Phase II trial for IMM01 combined with Pembrolizumab in R/R cHL patients showed an ORR of 69.7% and a CR rate of 24.2%[31] - The median duration of response (DoR) for the combination therapy was 21.2 months, with an 18-month overall survival (OS) rate of 91.6%[31] - The company plans to explore the efficacy potential of IMM01 in other indications and seek collaboration opportunities[21] - The company received IND approval for the IMM2510 combined chemotherapy trial for NSCLC in November 2023, with the first patient dosed in December 2024[33] - The company has initiated clinical trials for IMM0306, with 18 evaluable patients as of September 10, 2025, showing SRI-4 response rates of 71.4% and 80% for different dosage groups[46] - The company has initiated a phase II trial for ESCC and SQ-NSCLC as neoadjuvant/adjuvant therapy, with trials expected to start in December 2025[37] - The company has initiated a phase II trial for first-line endometrial cancer, expected to start in January 2026[37] - The company has dosed the first patient in the phase I study of IMM2520 for solid tumors, with 26 patients recruited as of December 31, 2025[45] Financial Performance - Revenue for the year ended December 31, 2025, was RMB 154.3 million, an increase of RMB 80.2 million compared to RMB 74.1 million for the year ended December 31, 2024[16] - The company reported total revenue of RMB 154,294,000 for the year ended December 31, 2025, a significant increase from RMB 74,149,000 in 2024, representing a growth of 108.3%[108] - The company reported a gross profit of RMB 153,184,000 for 2025, compared to RMB 74,149,000 in 2024, indicating a gross margin improvement[108] - Revenue from collaborative development surged to RMB 79,290,000 in 2025, compared to RMB 2,668,000 in 2024, indicating a growth of 2,769.5%[118] - Revenue from licensing fees remained stable at RMB 71,441,000 in 2025, slightly up from RMB 71,342,000 in 2024[118] - The company reported a pre-tax loss of RMB 219,259,000 for the year ended December 31, 2025, an improvement from a loss of RMB 316,590,000 in 2024[136] - The company reported a net loss of RMB 7.6 million for the year ended December 31, 2025, an improvement from a net loss of RMB 11.5 million in 2024[56] - The net loss for the year decreased from RMB 316.6 million in 2024 to RMB 219.3 million in 2025[62] - Adjusted net loss for 2025 is RMB 203.5 million, compared to RMB 255.0 million in 2024, after excluding share-based payment expenses and property and equipment impairment losses[64] - Basic and diluted loss per share improved to RMB (0.53) in 2025 from RMB (0.84) in 2024[108] - The company reported a loss attributable to shareholders of RMB 218,580,000 for the year ended December 31, 2025, compared to a loss of RMB 315,855,000 in 2024, representing a 30.8% improvement[137] - The company did not declare or pay any dividends for the fiscal year 2025, consistent with 2024[140] Expenses and Costs - Research and development expenses remained stable at RMB 322.8 million for the year ended December 31, 2024, and RMB 322.3 million for the year ended December 31, 2025[16] - R&D expenses for the year ended December 31, 2025, are RMB 322.3 million, slightly down from RMB 322.8 million for 2024, primarily due to a decrease in preclinical and CMC expenses by RMB 9.8 million and share-based payments by RMB 10.8 million[58] - Clinical trial expenses increased by RMB 15.2 million, mainly due to ongoing clinical development of IMM01 and IMM2510[58] - Administrative expenses decreased by 16.8% from RMB 64.8 million in 2024 to RMB 53.9 million in 2025, attributed to a reduction in share-based payments[59] - Financial costs rose from RMB 3.4 million in 2024 to RMB 5.3 million in 2025, mainly due to increased borrowing interest[60] - The total depreciation expense for the year was RMB 14,610,000, down from RMB 20,681,000 in the previous year[131] Cash Flow and Liquidity - Cash and cash equivalents increased to RMB 1,016.0 million as of December 31, 2025, from RMB 752.1 million in 2024, mainly due to net proceeds from new share issuance of RMB 315.5 million and increased bank loans of RMB 98.6 million[66] - Net cash used in operating activities increased to RMB 202.6 million in 2025 from RMB 128.0 million in 2024, primarily due to a decrease in trade and other payables[67] - The net cash from financing activities increased to RMB 402.4 million in 2025 from RMB 258.9 million in 2024, mainly due to proceeds from new share issuance and increased bank loans[68] - The company has approximately RMB 115.0 million of undrawn bank loan facilities as of December 31, 2025, indicating a strong liquidity position for future operational needs[69] - As of December 31, 2025, the company's debt-to-asset ratio increased to 28.1% from 26.4% as of December 31, 2024, primarily due to an increase in bank borrowings of RMB 986 million[70] - The company had unsecured bank borrowings of RMB 2.14 billion as of December 31, 2025, compared to RMB 1.154 billion as of December 31, 2024, with interest rates ranging from 2.80% to 3.25%[71] Shareholder and Corporate Governance - The company is committed to maintaining high standards of corporate governance to protect shareholder interests[80] - The company has no contingent liabilities as of December 31, 2025[73] - The company has no capital commitments as of December 31, 2025[72] - The company has no pledged assets as of December 31, 2025[74] - The company issued a total of 431,507,695 shares, including 420,477,305 H-shares, as of the announcement date[84] - The net proceeds from the global offering amounted to approximately HKD 251.3 million after deducting underwriting commissions and related costs[85] - The company has regained global rights for IMM2510 and IMM27M, enhancing its portfolio and commitment to accelerate clinical development for these assets[93] - A loan agreement was established with a major shareholder for a principal amount of RMB 13,724,673.60, indicating ongoing financial transactions within the company[94] Future Plans and Strategies - The company plans to present updated data on SQ-NSCLC at the 2026 ASCO conference[7] - The company plans to expand its overseas footprint and accelerate clinical research in China to leverage market opportunities[50] - The company aims to address unmet medical needs through a phased clinical development strategy for its drug candidates[50] - The company plans to utilize the unallocated proceeds from the 2024 placement by mid-2027 and from the 2025 placement by mid-2028[98][102] - The company plans to establish a new production facility in Zhangjiang Science City, Shanghai, although no funds have been allocated yet for this purpose[88]

Financial Performance - The company reported a revenue of RMB 712.9 million for the year ended December 31, 2025, representing a year-on-year growth of 15.8%[4]. - Gross profit increased to RMB 486.1 million, with a gross margin of 68.2%[4][12]. - The company reported a segment loss of RMB 215,142 thousand for the total operations, with the transcatheter valve therapy segment contributing a loss of RMB 215,517 thousand[29]. - Total revenue for the year ended December 31, 2025, reached RMB 712,870 thousand, an increase from RMB 615,483 thousand in 2024, representing a growth of approximately 15.9%[29]. - The net financial (cost) income for 2025 was a loss of RMB 3,929 thousand, a decline from a net income of RMB 17,744 thousand in 2024[39]. - The basic loss per share for the year ended December 31, 2025, was RMB (0.31), compared to RMB (0.34) for the year ended December 31, 2024, reflecting a slight improvement in loss per share[43]. - The company did not declare or pay any dividends for the year ended December 31, 2025, consistent with 2024[45]. - The company reported a pre-tax loss of RMB (202,599) thousand for 2025, an improvement from a loss of RMB (221,601) thousand in 2024[42]. - The net assets decreased to RMB 1,858.09 million as of December 31, 2025, from RMB 2,044.60 million in 2024[19]. Expenses and Cost Management - Sales and distribution expenses decreased by 2.3% to RMB 320.8 million, while administrative expenses fell by 16.6% to RMB 126.0 million[4]. - Total expenses for sales costs, sales and distribution expenses, administrative expenses, and R&D expenses amounted to RMB 928,012 thousand in 2025, an increase from RMB 864,722 thousand in 2024, representing a growth of approximately 7.3%[36]. - R&D service expenses increased significantly to RMB 104,806 thousand in 2025 from RMB 42,498 thousand in 2024, indicating a growth of approximately 147.5%[36]. - The sales and distribution expenses totaled RMB 320,813 thousand, highlighting the significant investment in market outreach and customer engagement[29]. - Administrative expenses decreased by 15.3% year-on-year to RMB 101.9 million, with the administrative expense ratio declining by 11.1 percentage points to 35.1%[13]. - The sales and distribution, administrative, and R&D expense ratios improved, decreasing by 3.5, 3.2, and 4.4 percentage points to 23.4%, 4.8%, and 9.8% respectively[15]. Research and Development - Research and development expenses rose by 25.0% to RMB 254.4 million, reflecting the company's commitment to innovation[4]. - The total R&D expenditure for the year was RMB 254,361 thousand, reflecting the company's commitment to innovation and development in medical devices[29]. - The internal R&D team consists of 152 employees focused on transcatheter valve therapy products and neurointerventional product development as of December 31, 2025[102]. - The company has developed next-generation products based on clinical feedback to optimize existing product performance and is actively advancing related iterative product development and registration[98]. - The company is actively involved in the research and development of innovative technologies for treating intracranial vascular diseases[162]. Product Development and Innovation - The company achieved a significant increase in segment profit for the neurointervention business, which grew by 86.6% to RMB 97.2 million[4][6]. - TAVR-related product sales reached RMB 290.1 million, up 11.6% year-on-year, driven by the successful launch of the TaurusMax® system[5]. - Neurointervention product sales increased by 18.9% to RMB 422.8 million, supported by strong performance of core products[5]. - The company has established a separate reporting segment for its cutting-edge technology business, which focuses on innovative solutions for heart valve diseases[28]. - The company is engaged in the development of medical devices for neurovascular diseases, with a focus on minimally invasive treatments[162]. - The company is exploring market expansion opportunities in the cardiovascular intervention sector, particularly through minimally invasive techniques[168]. Regulatory Approvals and Market Expansion - The TaurusTrio® TAV system received regulatory approval, marking a significant milestone in the company's product offerings[8]. - The DCwire® microguidewire received FDA approval in March 2026, marking a significant milestone for the company's global expansion strategy[16]. - The YonFlow® flow-directed stent received regulatory approval in April 2025, leading to its first commercial implant in June 2025, contributing significant incremental revenue[110]. - The registration application for the NRcoil® detachable coil was approved by the National Medical Products Administration in August 2023, offering a new option for embolization procedures[88]. - The company has established strong relationships with global leaders in transcatheter valve therapy and neurointerventional fields, enhancing its R&D capabilities[99]. Strategic Focus and Future Outlook - The group aims to maintain its leadership position in the Chinese TAVR market and expand its international presence in structural heart and neurovascular intervention therapies by 2030[112]. - The group plans to continue advancing the registration of the TaurusTrio® TAV system and the GeminiOne® TEER system, enhancing its product portfolio to meet unmet clinical needs[112]. - The neurointervention business is expected to enter the initial phase of global expansion by 2026, with plans for overseas regulatory registration and market access initiatives[114]. - The group will explore suitable global financing opportunities to support the development of cutting-edge treatment solutions and expand the accessibility of advanced technologies[113]. - The company is committed to ongoing research and development of new products and technologies in the field of interventional cardiology[168]. Corporate Governance and Compliance - The financial statements are prepared in accordance with the International Financial Reporting Standards, ensuring compliance and transparency in financial reporting[21]. - The audit committee has reviewed the consolidated financial statements for the reporting period and found them compliant with applicable accounting standards and regulations[153]. - The company has adopted a standard code for securities trading for directors and senior management, confirming compliance for the reporting period[151]. - The company is committed to adhering to the corporate governance code as outlined in the listing rules[160].

Financial Performance - For the fiscal year ending December 31, 2025, the company reported total revenue of RMB 3,650,459,000, a decrease of 48.3% compared to RMB 7,066,784,000 in 2024[6]. - Gross profit for the same period was RMB 2,134,559,000, down 48.5% from RMB 4,143,040,000 in the previous year[6]. - The net profit attributable to equity shareholders was RMB 538,469,000, reflecting a decline of 59.3% from RMB 1,323,622,000 in 2024[6]. - Adjusted net profit (non-IFRS measure) was RMB 523,394,000, a decrease of 68.8% compared to RMB 1,676,275,000 in 2024[6]. - The company experienced a net cash outflow from operating activities of RMB 885,612,000, contrasting with a net cash inflow of RMB 781,003,000 in the previous year, marking a 213.4% change[6]. - The gross margin for 2025 was 58.5%, slightly down from 58.6% in 2024, while the net margin decreased to 14.8% from 18.7%[8]. - The company achieved a 100% renewable energy usage milestone during the reporting period, with a 6.27% year-on-year reduction in electricity density and a 12.12% reduction in natural gas consumption density by 2025[42]. - The company reported other income of RMB 285,959,000 in 2025, compared to RMB 309,765,000 in 2024, a decline of approximately 7.7%[103]. - Total income tax expense for 2025 was RMB 183,378,000, a significant decrease of 67.9% compared to RMB 570,710,000 in 2024[109]. - The company’s total liabilities increased to RMB 2,315,113,000 in 2025 from RMB 1,424,776,000 in 2024, reflecting a growth of 62.5%[118]. Brand Performance - The flagship brand, Zhenjiu, contributed approximately 52.6% of total revenue, focusing on high-quality liquor products in the mid-to-high price range[12]. - Revenue from the brand Zhenjiu fell by 57.1% to RMB 1,921.3 million, primarily due to weak market demand and inventory reduction measures[50]. - Revenue from the brand Lidu decreased by 17.3% to RMB 1,085.4 million, attributed to a significant contraction in high-end liquor consumption[50]. - Revenue from the brand Xiangjiao declined by 41.6% to RMB 468.3 million, impacted by challenging market conditions[50]. - "Li Du" brand contributed approximately 29.7% of the company's revenue for the year ending December 31, 2025, and is strategically expanding nationwide from its base in Jiangxi Province[15]. - "Xiang Jiao" contributed approximately 12.8% of the company's revenue for the year ending December 31, 2025, and has a strong brand presence in the Hunan market[18]. - "Kai Kou Xiao" contributed approximately 2.8% of the company's revenue for the year ending December 31, 2025, focusing on the mid-range market with upgraded products[19]. Product Development and Innovation - The company launched multiple new product lines in 2025, including the high-end "Zhen 50" series and the "Zhen 2020" vintage wine, enhancing market penetration[14]. - The introduction of new products like "Tie Gai Long Jiang" and "Tie Gai Long Jiang • Hong Yun" reflects the company's strategic focus on the mid-range banquet market[18]. - The product development team consists of 275 employees, with a significant majority holding bachelor's degrees or higher, and is led by a technical committee of 94 industry experts[20]. - The company continues to develop unique cultural products inspired by historical artifacts, enhancing its product matrix and brand storytelling[14]. - The R&D team has received multiple awards and patents, contributing to the establishment of national and local standards in the industry[21]. Strategic Initiatives - The company launched the "Wanshang Alliance" model in June 2025 to enhance distribution efficiency and profitability amid declining consumer demand[10]. - The company aims to optimize production costs and marketing expenses while maintaining a disciplined sales pace to alleviate distributor pressure[10]. - The company launched an innovative "Ten Thousand Merchants Alliance" model in June 2025 to address industry challenges and enhance sales through a controlled national network of retailers[24]. - The company anticipates that the new alliance model will enhance competitiveness and attract end consumers by providing attractive channel profit margins while maintaining strict supply controls[33]. - The company is enhancing its production capacity with new facilities expected to be operational in the first half of 2026, including a packaging plant and a new distillery[44]. Digital Transformation - The company has implemented a comprehensive digital management system to optimize operations and improve profitability through data analysis[26]. - A unique digital coding system for base liquor containers has been developed to enhance management efficiency and asset security[27]. - The company has constructed an intelligent weighing system that integrates video monitoring and automatic weighing to improve accuracy and efficiency[27]. - The company has partnered with Huawei to build an advanced IoT platform infrastructure, which is foundational for the next generation of its digital production system[27]. - The company has developed a proprietary WeChat mini-program and application to interact directly with end consumers and real-time collect and analyze key performance indicators, optimizing channel inventory levels[28]. - The digital quality management system (QMS) has completed 165,556 inspections across 15 categories during the reporting period, enhancing quality traceability from raw materials to final product delivery[28]. - The company upgraded its digital coding system for its premium products, increasing from a four-code to a six-code system, which includes NFC anti-counterfeiting measures[28]. - The company has implemented over 100 robotic process automation (RPA) scenarios across finance, logistics, human resources, and operations, significantly reducing labor costs and human errors[30]. - The digital transformation has led to higher operational efficiency and profitability, enabling data-driven decision-making and direct consumer engagement[31]. Corporate Social Responsibility - The company donated a total of RMB 14.52 million to social welfare activities by 2025, with employees contributing 37,249 hours of volunteer service[43]. - The company recycled and repurposed 17,025 discarded bottles in 2025 as part of its "Bottle Recycling Cultural Project," promoting sustainability[41]. - The company’s ESG rating improved to "AAA," ranking first among 58 listed beverage companies, reflecting its commitment to sustainability[43]. Governance and Compliance - The company has complied with all provisions of the corporate governance code as of December 31, 2025[130]. - The board of directors includes both executive and non-executive members, ensuring diverse governance[139]. - The company adopted an equity incentive plan on April 11, 2023, for participants post-IPO[137]. - The annual general meeting is scheduled for June 16, 2026, with a notice to be published on April 24, 2026[133].

Financial Performance - For the fiscal year ending December 31, 2025, the total revenue of Grand Power Logistics Group Limited was approximately HKD 723.6 million, a decrease of about 31.6% compared to HKD 1,058.2 million for the fiscal year 2024[12]. - The air freight forwarding services generated revenue of HKD 716.7 million, accounting for 99.04% of total revenue, while sea freight forwarding services contributed HKD 6.9 million, or 0.96%[13]. - The decline in revenue was attributed to the impact of newly implemented U.S. tariffs, which significantly reduced demand for the company's freight forwarding services, and intensified industry competition that pressured pricing[12]. - The group's air cargo transit revenue decreased by approximately 31.4% to about HKD 716,700,000 for the fiscal year 2025, compared to approximately HKD 1,045,000,000 for fiscal year 2024[14]. - The group's sea cargo transit revenue decreased by approximately 47.4% to about HKD 6,900,000 for the fiscal year 2025, compared to approximately HKD 13,200,000 for fiscal year 2024[15]. - The group recorded a gross loss of approximately HKD 200,000 for the fiscal year 2025, with a gross loss margin of about 0.03%, compared to a gross profit of approximately HKD 39,700,000 and a gross profit margin of about 3.76% for fiscal year 2024[17]. - The group reported a net loss of approximately HKD 44,900,000 for the fiscal year 2025, significantly increased from approximately HKD 3,700,000 for fiscal year 2024[23]. - The total assets decreased to HKD 208,004,000 in 2025 from HKD 270,343,000 in 2024, a decline of 23.1%[187]. - The company's equity decreased to HKD 81,065,000 in 2025 from HKD 126,655,000 in 2024, a decline of 36.0%[188]. - The company reported a significant impairment loss of HKD 2,438,000 on property, plant, and equipment in 2025[185]. Cost Management - Service costs decreased by approximately 28.9% to about HKD 723,800,000 for the fiscal year 2025, compared to approximately HKD 1,018,400,000 for fiscal year 2024[16]. - The group anticipates an overall cost increase of up to 10% due to rising container freight rates and surcharges, influenced by geopolitical tensions and supply chain disruptions[40]. - The group is accelerating strategy adjustments by developing alternative routes and transportation modes to avoid affected channels and investing in digital tools to enhance operational efficiency[40]. Financial Position - As of December 31, 2025, the group's debt-to-equity ratio was approximately 74.9%, compared to 38.0% as of December 31, 2024[24]. - The group's cash and bank balances increased to approximately HKD 39,100,000 as of December 31, 2025, from approximately HKD 31,300,000 as of December 31, 2024[25]. - Trade receivables decreased by approximately 35.4% to about HKD 130,200,000 as of December 31, 2025, compared to approximately HKD 201,400,000 as of December 31, 2024[26]. - Interest-bearing borrowings amounted to approximately HKD 58,900,000 as of December 31, 2025, compared to approximately HKD 46,900,000 as of December 31, 2024[27]. - The company had cash and bank balances of HKD 39,084,000 in 2025, an increase from HKD 31,263,000 in 2024, representing a growth of 25.1%[187]. Governance and Management - The management team is led by Zhao Tong, who serves as the chairman and CEO, ensuring strategic direction[53]. - The company is focused on risk management and financial oversight, with a dedicated team to monitor these functions[44][46]. - The board includes independent non-executive directors with extensive experience in corporate finance and risk management, enhancing governance[47][49][51]. - The company emphasizes corporate governance and compliance, reflecting its commitment to transparency and accountability[52]. - The board has established regular meetings, occurring at least quarterly, to ensure effective governance and oversight[124]. Employee and Culture - The total employee cost for the fiscal year 2025 was approximately HKD 16.7 million, compared to HKD 17.6 million for fiscal year 2024, with a total of 34 full-time employees as of December 31, 2025[39]. - The company emphasizes employee training and development to maximize their potential, viewing employees as crucial assets for sustainable growth[39]. - The company emphasizes a culture of teamwork, integrity, innovation, and continuous improvement to drive organizational performance and sustainable growth[109]. - The company is committed to promoting gender diversity at all levels, with specific resources allocated for the career development of female employees[123]. Risk Management - The company has established a risk management and internal control system to identify existing risks and has taken necessary measures to mitigate identified risks[88]. - Economic risks include the inability to respond to macroeconomic factors affecting revenue and profitability, particularly in the context of global economic slowdown[89]. - The group faces foreign exchange risks primarily due to certain financial assets and liabilities being denominated in currencies other than the functional currencies of its entities[38]. - The group will regularly assess customer credit ratings and adjust their credit terms and payment conditions to minimize the risk of defaults and cash flow mismatches[154]. Shareholder Information - The company has adopted a shareholder communication policy to ensure timely, transparent, and accurate communication with shareholders, including financial reports and other relevant documents[159]. - Shareholders holding at least 10% of the paid-up capital have the right to request the board to convene a special general meeting within two months of the request[156]. - The company maintains a public float of 26.84%, with a total of 307,575,000 shares outstanding, including 112,500,000 shares each held by Profit Virtue and Peak Connect[95]. Audit and Compliance - The total fees paid or payable to auditors for the fiscal year 2025 amounted to HKD 857,000, with HKD 750,000 for audit services and HKD 107,000 for non-audit services[155]. - The independent auditor's report confirms that the financial statements present a true and fair view of the group's financial performance and cash flows for the fiscal year[169]. - The company has adopted a code of conduct for securities trading, ensuring compliance with GEM listing rules and preventing insider trading[129].

Branding and Market Position - The company successfully rebranded as Financial Street Securities Co., Limited, enhancing its overall brand value and market influence[11]. - The company aims to expand its market presence and enhance its product offerings through strategic investments and partnerships[19]. - The company is actively monitoring regulatory changes that could impact its operations, demonstrating a proactive approach to compliance and risk management[19]. Financial Performance - The company's operating revenue and total profit steadily increased, with wealth management becoming a key growth driver, achieving record highs in new effective accounts and assets[11]. - Total operating revenue for 2025 reached RMB 3,543,050, an increase of 27.16% compared to RMB 2,786,214 in 2024[51]. - Pre-tax profit for 2025 was RMB 214,889, reflecting a significant growth of 48.74% from RMB 144,476 in 2024[51]. - Net profit attributable to ordinary shareholders for 2025 was RMB 324,944, an increase of 84.33% from RMB 176,283 in 2024[51]. - Total assets as of December 31, 2025, amounted to RMB 43,000,392, a growth of 7.55% from RMB 39,981,081 in 2024[53]. - Total liabilities increased to RMB 34,147,558, representing a 9.19% rise from RMB 31,274,058 in 2024[53]. - The weighted average return on equity for 2025 was 3.85%, up from 2.16% in 2024, an increase of 1.69 percentage points[51]. - The asset-liability ratio decreased to 60.35% as of December 31, 2025, down from 62.60% in 2024[53]. Business Operations and Growth - The investment advisory business significantly improved its industry ranking, while proprietary investment operations yielded favorable returns[11]. - The company initiated comprehensive reforms in Xinhua Fund, with notable collaborative expansion results in Beijing and Chongqing regions[11]. - The bond underwriting business of Hengtai Changcai experienced steady growth, with precise implementation of business mechanisms at the Beijing Stock Exchange[11]. - The company is advancing the "institution + industry + retail" business model in Hengtai Futures, which is maturing[11]. - The company aims to enhance its professional capabilities and expand its market share in key regions such as Shandong, Guizhou, Jilin, and Jiangsu[98]. - The company plans to deepen its focus on industries such as new energy, new technology, and high-end manufacturing to drive significant growth in equity business[95]. Compliance and Risk Management - The company aims to enhance compliance risk control and internal control mechanisms, ensuring a robust compliance risk management framework[12]. - The company established an internal control and risk management system to mitigate various operational risks, including strategic, credit, market, liquidity, operational, and legal compliance risks[19]. - Credit risk management is a priority, with measures in place for both financing and investment-related credit risks, including internal credit ratings and risk monitoring[200]. Capital Structure and Investments - The registered capital of the company is RMB 2,604,567,412[23]. - The net capital of the company is RMB 6,429,811,738.51[23]. - The company holds a 52.99% stake in Xinhua Fund Management Co., Ltd., indicating a strong position in the asset management sector[16]. - Financial Street Capital operates as a major shareholder, holding 62.06% of Financial Street Investment, which is a subsidiary of the State-owned Assets Supervision and Administration Commission[19]. - The company has a 95.10% ownership in Hengtai Futures Co., Ltd., enhancing its capabilities in futures trading and investment services[16]. Revenue Sources and Business Segments - The brokerage and wealth management business generated operating revenue of RMB 2,183.23 million, up 32.17% from 2024[79]. - Investment banking revenue was RMB 179.64 million in 2025, representing 5.07% of total revenue, slightly down from 5.09% in 2024[166]. - Proprietary trading revenue increased to RMB 843.67 million in 2025, making up 23.81% of total revenue, compared to RMB 660.39 million or 23.70% in 2024[166]. - Investment management reported a loss of RMB 572.56 million in 2025, with a negative margin of 266.44%, worsening from a loss of RMB 255.35 million or 176.75% in 2024[169]. Future Plans and Strategic Initiatives - The company plans to enhance its wealth management services and digital operations, focusing on a customer-centric approach and strategic development in 2026[83]. - The company aims to improve its professional competence and build a specialized equity business team to enhance its competitive edge[95]. - By 2026, the company plans to focus on a light capital business model while maintaining a balance with heavy capital operations, aiming for a differentiated advantage[199]. - The company is developing a buyer service system centered on strategy research, investment advisory, and financial product allocation[199].

Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 894,584,000, a decrease of 12.4% compared to RMB 1,021,063,000 in 2024[3] - Gross profit for the same period was RMB 589,772,000, down 12.6% from RMB 674,423,000, with a gross margin of 65.9%[3] - The net loss attributable to shareholders was RMB 59,132,000, representing a significant increase of 212.5% from RMB 18,924,000 in the previous year[3] - Basic loss per share was RMB 5.50, compared to RMB 1.76 in 2024, reflecting a 212.5% increase in losses[4] - The company reported a total comprehensive loss of RMB 68,935,000 for the year, compared to RMB 19,099,000 in 2024[7] - The group recorded a pre-tax loss of RMB 52,689,000 for 2025, compared to a loss of RMB 11,503,000 in 2024, indicating a significant increase in losses[29] - The group confirmed an impairment loss provision of approximately RMB 8.4 million for property, plant, and equipment, and right-of-use assets due to ongoing losses from certain restaurants[47] Revenue Breakdown - Revenue from restaurant operations was RMB 889.5 million, down from RMB 1,014.7 million in the previous year, reflecting a decline of 12.3%[17] - The revenue from banquet-related services increased by over 100% year-on-year, with its contribution to overall dining revenue rising from approximately 7.9% to about 25.7%[39] - The contribution of the takeaway business to total revenue increased from approximately 11.6% last year to about 16.8% this year[40] - The average customer spending for the main brand, Tang Palace, was RMB 218.7 in 2025, down from RMB 229.6 in 2024, while its revenue contribution rose to 85.0%[45] Assets and Liabilities - Total assets decreased to RMB 636,259,000 in 2025 from RMB 760,428,000 in 2024, indicating a decline in overall asset value[8] - Current liabilities slightly decreased to RMB 387,732,000 from RMB 388,890,000, showing stability in short-term obligations[8] - The company reported a net current liability of approximately RMB 26.5 million as of December 31, 2025, which includes contract liabilities of about RMB 253.0 million related to dining services[1] - The total assets and net assets of the group as of December 31, 2025, were approximately RMB 672.3 million and RMB 125.5 million, respectively, compared to RMB 760.4 million and RMB 205.2 million as of December 31, 2024[49] - The current ratio as of December 31, 2025, was 0.9, down from 1.1 as of December 31, 2024[50] Cash Flow and Liquidity - The company's cash and cash equivalents dropped to RMB 170,009,000 from RMB 328,281,000, indicating a significant reduction in liquidity[8] - The group reported a net cash inflow from operating activities of approximately RMB 43.4 million for the year[48] - The net cash outflow from investing activities was approximately RMB 134.9 million, including property, plant, and equipment purchases of approximately RMB 13.4 million[48] - Cash and cash equivalents decreased by approximately RMB 158.3 million, from RMB 328.3 million as of December 31, 2024, to RMB 170.0 million as of December 31, 2025[48] - The group had approximately RMB 125.0 million in restricted time deposits as of December 31, 2025[55] Operational Changes - The number of self-operated restaurants decreased to 30 from 32, while the number of joint venture restaurants fell to 12 from 17[3] - The group employed approximately 2,300 employees as of December 31, 2025, down from approximately 2,600 employees as of December 31, 2024[53] - Employee costs totaled RMB 375,962,000 in 2025, down from RMB 422,729,000 in 2024, reflecting a reduction of about 11.0%[29] - The employee cost as a percentage of revenue increased to 42.0% from 41.3% in the previous year, excluding share-based payment expenses[46] Strategic Focus - The group focused on market development in major first-tier and new first-tier cities in mainland China and Hong Kong[38] - The group aims to stabilize business across regions with targeted strategies for different consumer groups in mainland China and Hong Kong[38] - The group plans to enhance its marketing strategy in 2026 by improving membership systems and optimizing service experiences to deepen connections with members[44] - The group aims to continue its light-asset opening strategy to increase revenue and accelerate profit contribution time[44] Customer and Market Insights - No single customer accounted for more than 10% of the group's total revenue, indicating a diversified customer base[23] - The number of consumers reducing dining out for business or social gatherings was reported at 24.2%, indicating a shift in consumer behavior[38] - In Hong Kong, the group operates three self-managed stores, facing pressure on dine-in revenue due to local residents' consumption shifting to mainland markets[42] Miscellaneous - The company has not declared any dividends for the year, maintaining a focus on financial recovery[3] - The group had no bank borrowings as of December 31, 2025, maintaining a capital debt ratio of zero[49] - The board believes that the group has sufficient working capital for its operations and expansion in the foreseeable future[51] - No significant acquisitions or disposals of subsidiaries, associates, or joint ventures occurred during the year[59] - The annual performance announcement will be published on the Hong Kong Stock Exchange website and the company's website[70] - The board expresses gratitude to management, employees, shareholders, business partners, and auditors for their support during the year[71]

Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 41,931,000, a decrease of 28.7% compared to RMB 58,814,000 in 2024[3] - Gross profit for the same period was RMB 3,417,000, down 55.5% from RMB 7,668,000 in 2024[3] - The company reported a loss before tax of RMB 12,051,000, compared to a loss of RMB 11,617,000 in the previous year, indicating a 3.7% increase in losses[3] - The group reported a pre-tax loss of RMB 12,051,000 for the year ending December 31, 2025, compared to a pre-tax loss of RMB 11,617,000 for the previous year[21] - The company reported a loss of approximately RMB 12,051,000 for the year ending December 31, 2025, an increase of 3.7% from RMB 11,617,000 in 2024[45] Assets and Liabilities - Total assets decreased to RMB 35,492,000 in 2025 from RMB 47,864,000 in 2024, reflecting a decline of 25.8%[4] - The total assets of the group as of December 31, 2025, were RMB 46,756,000, down from RMB 60,202,000 in 2024, representing a decline of approximately 22.3%[61] - The group's total liabilities increased slightly to RMB 39,234,000 as of December 31, 2025, compared to RMB 40,629,000 in 2024, indicating a decrease of about 3.4%[61] - The company's total equity dropped to RMB 7,522,000 in 2025 from RMB 19,573,000 in 2024, a decrease of 61.6%[5] Cash Flow - The company had cash and cash equivalents of RMB 16,249,000 at the end of 2025, down from RMB 28,528,000 in 2024, representing a decline of 43.0%[4] - The group had net cash outflows of approximately RMB 13,238,000 for the year ended December 31, 2025, compared to RMB 6,685,000 in 2024[48] Revenue Breakdown - The group reported total sales revenue of RMB 41,931,000 for the year ending December 31, 2025, with software product sales contributing RMB 2,529,000 and hardware product sales contributing RMB 3,370,000[13] - The revenue from technical support services and others decreased by approximately 36.2% year-on-year, primarily due to clients reducing their capital expenditures[43] - Major clients contributed over 10% of total sales, with Client A generating RMB 15,182,000 in 2025 and RMB 33,833,000 in 2024, while Client B generated RMB 13,856,000 in 2025 and RMB 11,042,000 in 2024[27] Expenses - The group incurred employee costs totaling RMB 39,457,000 in 2025, down from RMB 55,954,000 in 2024[29] - Management expenses decreased by 12.2% to approximately RMB 10,832,000, mainly due to the closure of the Hong Kong office and reduced employee costs[44] - Research and development expenses decreased by 21.9% to approximately RMB 6,167,000, compared to RMB 7,893,000 in 2024[45] Compliance and Governance - The company has adhered to the corporate governance code, except for deviation from code provision C.2.1, as of the year ending December 31, 2025[69] - The position of CEO has been vacant since November 1, 2022, following the resignation of Mr. Lin Xuexin, and the board is actively seeking a suitable candidate[70] - Deloitte has agreed that the preliminary financial data for the year ending December 31, 2025, aligns with the audited financial statements to be approved on March 25, 2026[72] Future Outlook - The company aims to enhance its product capabilities and customer value orientation while transitioning to a more sustainable revenue model[38] - The overall industry outlook is expected to improve gradually, transitioning from short-term pressure to structural recovery[40]

Financial Performance - For the fiscal year ending December 31, 2025, the group's revenue was approximately RMB 6,547.71 million, an increase of 4.42% compared to RMB 6,270.74 million in 2024[4] - The net profit attributable to equity shareholders for the fiscal year was approximately RMB 2,245.14 million, reflecting an increase of 11.17% from RMB 2,019.56 million in 2024[4] - The group's core net profit, excluding profits from joint ventures, was approximately RMB 724.24 million, up by 2.95% from RMB 703.50 million in 2024[4] - The total comprehensive income for the year was RMB 2,391.76 million, compared to RMB 2,081.01 million in 2024, indicating a significant increase[8] - The group's gross profit for the fiscal year was RMB 2,271.93 million, compared to RMB 2,175.42 million in 2024[5] - The operating profit for the year was RMB 1,592.04 million, slightly down from RMB 1,641.39 million in 2024[5] - The earnings per share for the year were RMB 1.32, compared to RMB 1.17 in 2024, showing an increase in profitability[5] - The reported segment profit before tax was RMB 2,455,622 thousand for 2025, up from RMB 2,249,669 thousand in 2024, indicating a growth of about 9.1%[25] - The company's pre-tax profit for 2025 was RMB 2,455,622,000, compared to RMB 2,249,669,000 in 2024, reflecting an increase of approximately 9.1%[38] Dividends and Shareholder Returns - The board proposed a final cash dividend of HKD 0.30 per share, with a total annual dividend of HKD 0.40 per share, including the interim dividend announced in August 2025[4] - The proposed final dividend per ordinary share for 2025 is HKD 0.30, totaling approximately RMB 473,712,000, consistent with the previous year's dividend[45] - The company declared a special dividend of HKD 0.10 per share in 2024, amounting to approximately RMB 163,971,000, which was fully paid on November 30, 2024[45] Assets and Liabilities - The total assets of the group increased, reflecting ongoing market expansion and strategic investments[6] - Non-current assets totaled RMB 75,316,433 thousand in 2025, an increase from RMB 74,510,651 thousand in 2024, reflecting a growth of approximately 1.08%[9] - The company's total liabilities increased to RMB 26,898,138 thousand in 2025 from RMB 24,931,372 thousand in 2024, representing a rise of about 7.87%[11] - The total equity attributable to shareholders was RMB 47,713,102 thousand in 2025, down from RMB 49,398,995 thousand in 2024, reflecting a decrease of about 3.43%[11] - The company's cash and cash equivalents decreased to RMB 2,072,398 thousand in 2025 from RMB 2,269,721 thousand in 2024, a decline of approximately 8.67%[9] - Current liabilities decreased to RMB 8,478,470 thousand in 2025 from RMB 6,251,413 thousand in 2024, indicating a reduction of approximately 35.67%[11] Revenue Breakdown - Revenue from waste disposal services was RMB 4,986,533,000, down from RMB 5,482,229,000 in 2024, indicating a decline of about 9.0%[19] - Revenue from new energy business significantly increased to RMB 1,093,066,000 from RMB 289,664,000 in 2024, marking a growth of approximately 277.5%[19] - Revenue from contracts with customers recognized over time was RMB 5,037,511,000, compared to RMB 5,192,613,000 in 2024, reflecting a decrease of about 3.0%[20] - Revenue from port logistics services was RMB 168,451,000, a slight decrease from RMB 182,353,000 in 2024, representing a decline of approximately 7.6%[19] - Income from BOT arrangements for waste disposal from local government agencies was RMB 2,085,195,000, down from RMB 2,317,185,000 in 2024, indicating a decrease of about 10.0%[19] Operational Highlights - The company received approximately 19.349 million tons of municipal solid waste, a year-on-year increase of 3%[63] - The company disposed of approximately 16.467 million tons of municipal solid waste, a year-on-year increase of 2%[63] - The group processed about 15.99 million tons of municipal waste, reflecting a year-on-year growth of 2%[65] - The total electricity generated and fed into the grid was approximately 5.42 billion kWh, which is a year-on-year increase of 6%[65] - The group sold approximately 698,000 tons of steam, marking a significant year-on-year growth of 85%[65] - The group has successfully connected two waste-to-energy projects in Yunnan Yuan Yang and Hubei Jing Shan to the grid during the reporting period[64] Employee and Compensation - As of December 31, 2025, the total number of employees is 6,557, a decrease from 6,607 employees on December 31, 2024[109] - Total employee compensation, including director remuneration, is approximately RMB 961.70 million, up from RMB 855.3 million in 2024[109] - Employee costs increased to 961,697 thousand RMB in 2025 from 855,256 thousand RMB in 2024, marking an increase of about 12.43%[31] Taxation and Financial Management - The income tax expense for the year was RMB 119,290,000, with a deferred tax expense of RMB 88,095,000, reflecting the company's tax obligations[34] - The applicable income tax rate for the company's subsidiaries in mainland China is 25%, with certain high-tech enterprises eligible for a reduced rate of 15%[37] - The company recognized a tax benefit of RMB (320,821,000) in 2025, compared to RMB (304,032,000) in 2024, indicating an increase in tax benefits[38] Future Outlook and Strategic Initiatives - The company plans to focus on enhancing core competitiveness and achieving healthy development across multiple industrial sectors in 2026[111] - The company aims to improve operational efficiency and market share in the waste-to-energy sector by optimizing capacity utilization and operational rates[112] - The new energy materials business will emphasize high-end product R&D and cost control, particularly in lithium iron phosphate materials[114] - The company will explore overseas markets for energy-saving equipment manufacturing and enhance its supply chain[112]

Financial Performance - For the fiscal year ending December 31, 2025, the company reported total revenue of HKD 145.574 million, a significant increase from HKD 176.764 million in the previous year, indicating a year-over-year growth of approximately 82.5%[4] - The gross profit for the same period was HKD 693,000, compared to HKD 18.883 million in the previous year, reflecting a decline in profitability[4] - The company incurred an operating loss of HKD 22.516 million, a decrease from an operating profit of HKD 4.565 million in the prior year, marking a substantial shift in operational performance[4] - The company reported a net loss attributable to equity holders of HKD 22.009 million, compared to a profit of HKD 1.073 million in the previous year, highlighting a significant downturn in financial performance[4] - The group reported a loss before tax of HKD 23,566,000 for the year ended December 31, 2025, compared to a profit of HKD 3,154,000 in 2024[25] - The company recorded a loss of approximately HKD 22.0 million for the period, compared to a profit of HKD 1.1 million in the same period last year, primarily due to project delays resulting in a revenue decrease of about HKD 31.2 million[51] - The group recorded a loss of approximately HKD 22.0 million for the period, compared to a profit of approximately HKD 1.1 million in the corresponding period of 2024[59] Assets and Liabilities - Total assets decreased to HKD 104.802 million from HKD 126.118 million, representing a decline of approximately 16.8%[5] - The company's net assets fell to HKD 44.732 million, down from HKD 66.738 million, indicating a reduction of about 32.9%[5] - The company’s cash and cash equivalents decreased to HKD 4.075 million from HKD 16.576 million, a decline of approximately 75.5%[5] - Non-current assets in Hong Kong as of December 31, 2025, amounted to HKD 281,000, a decrease from HKD 311,000 in 2024[21] - The company’s total liabilities due within one year are HKD 13,699,000 for 2025, down from HKD 17,565,000 in 2024, a decrease of approximately 22.0%[48] - The company’s warranty payables due within one year are HKD 2,316,000 for 2025, compared to HKD 2,535,000 in 2024, indicating a decrease of about 8.6%[43] - The total borrowings decreased from approximately HKD 25.2 million to approximately HKD 20.4 million[60] Revenue Sources - Revenue from external customers in Hong Kong for the year ended December 31, 2025, was HKD 143,586,000, down 17.9% from HKD 174,784,000 in 2024[20] - Major customer A contributed HKD 133,634,000 to total revenue in 2025, a decrease of 5.8% from HKD 141,929,000 in 2024[22] - The expected revenue from unfulfilled construction contracts as of December 31, 2025, is HKD 252,572,000 within one year and HKD 377,437,000 beyond one year[19] - The company recognized revenue of HKD 15,659,000 from contract assets in 2025, up from HKD 11,149,000 in 2024[30] Cost and Expenses - Total material costs for the year ended December 31, 2025, were HKD 44,605,000, down 28.0% from HKD 61,812,000 in 2024[23] - The sales cost reduced from approximately HKD 157.9 million to approximately HKD 144.9 million, a decrease of about 8.2%[54] - Gross profit fell from approximately HKD 18.9 million to approximately HKD 0.7 million, with the gross margin dropping from about 10.7% to approximately 0.5%[55] - Employee costs, including director remuneration, amounted to approximately HKD 31.7 million for the reporting period, compared to HKD 21.2 million in the previous year[70] Corporate Governance and Management - The company emphasizes strict cost control measures and quality management in project execution to address ongoing market challenges[50] - The company continues to monitor ongoing projects closely and seeks suitable bidding opportunities to enhance profitability and shareholder returns[51] - The chairman and CEO roles are held by the same individual, which the board believes is in the best interest of the group for effective management and business development[74] - The group is committed to maintaining good corporate governance standards to enhance accountability and transparency[73] Future Outlook and Risks - The group expects that the adoption of new or revised Hong Kong Financial Reporting Standards will not have a significant impact on its financial position or performance[15] - The group faces several key risks, including potential adverse impacts from pandemics, reliance on major clients, and the need for effective project cost estimation[79] - The company has secured a new project with a preliminary contract amount exceeding HKD 175 million for the second half of 2025[51] Shareholder Information - The company did not declare or pay any dividends for the year ended December 31, 2025, consistent with 2024[26] - The board does not recommend the distribution of a final dividend for the years ended December 31, 2025, and December 31, 2024[78] - The annual general meeting for the fiscal year 2025 is scheduled for May 21, 2026, and the annual report will be published on the company's website and the stock exchange website[82] - Share transfer registration will be suspended from May 15, 2026, to May 21, 2026, to determine shareholder attendance and voting rights at the annual general meeting[83] Audit and Compliance - The audit committee, composed of three independent non-executive directors, has reviewed the consolidated financial statements and believes they have been prepared in accordance with applicable accounting standards[80] - The group has adopted a code of conduct for directors' securities trading, ensuring compliance with GEM listing rules during the reporting period[76] - There have been no significant events occurring after December 31, 2025, up to the date of this announcement[71] - The group has not engaged in the purchase, sale, or redemption of any listed securities during the reporting period and held no treasury shares as of December 31, 2025[77]

Financial Performance - The total operating revenue for the year ended December 31, 2025, was RMB 2,905,052,655.48, a decrease of approximately 11.3% compared to RMB 3,276,220,087.81 in 2024[9]. - The net loss attributable to shareholders for the year was RMB 3,483,511,129.21, compared to a net loss of RMB 2,923,171,081.15 in 2024, indicating a worsening of approximately 19.2%[8]. - The total comprehensive income for 2025 was RMB -634.77 million, compared to RMB -322.80 million in 2024, indicating a significant decline in overall financial performance[12]. - Basic and diluted earnings per share for 2025 were both RMB -3.1779, worsening from RMB -2.1322 in 2024[12]. - The company generated a net cash flow from operating activities of RMB -58.35 million in 2025, reflecting ongoing financial challenges[18]. Assets and Liabilities - The total assets as of December 31, 2025, amounted to RMB 8,313,359,091.81, down from RMB 8,775,270,835.89 in 2024, reflecting a decrease of about 5.3%[5][8]. - The total liabilities increased to RMB 7,471,653,518.48 as of December 31, 2025, compared to RMB 7,298,790,640.87 in 2024, representing an increase of approximately 2.4%[7][8]. - The total current liabilities decreased to RMB 4,888,506,043.32 as of December 31, 2025, from RMB 5,278,197,075.01 in 2024, a reduction of approximately 7.4%[6]. - The long-term borrowings rose to RMB 2,239,187,459.44 in 2025, compared to RMB 1,648,971,583.00 in 2024, an increase of about 35.7%[7]. Accounts Receivable - The accounts receivable increased significantly to RMB 1,177,797,144.97 in 2025, compared to RMB 608,085,903.10 in 2024, reflecting an increase of about 93.5%[4]. - The accounts receivable aging report shows that receivables within one year increased significantly to approximately ¥1.15 billion in 2025 from ¥598.19 million in 2024[169]. - The accounts receivable balance as of December 31, 2025, is 1,192,576,563.23, with 764,867,405.81 being non-overdue and 294,615,726.14 overdue but not impaired[176]. - The provision for bad debts as of December 31, 2025, was approximately ¥14.78 million, with a bad debt ratio of 1.24%[170]. - The provision for bad debts for overdue accounts is 133,093,431.28, indicating a significant risk exposure[176]. Research and Development - Research and development expenses for 2025 were RMB 96,860,776.42, down from RMB 120,809,395.32 in 2024, a decrease of about 19.8%[9]. - There is a commitment to increase R&D efforts, focusing on new materials, technologies, and product innovations to drive high-quality development[21]. - The company’s subsidiaries Hefei Photovoltaic, Yan'an New Energy, and Jiangxi Photovoltaic are eligible for additional tax deductions on R&D expenses, allowing for 100% pre-tax deductions starting January 1, 2023[165]. Market Strategy - The company aims to expand and solidify its domestic and international markets through differentiated competitive strategies and deeper customer collaboration[21]. - The company has implemented a strategy to enhance its market presence through technological advancements and tax incentives for R&D activities[165]. Financial Support and Compliance - The company has received financial support commitments from China Electronics and has access to significant unused credit facilities from banks, ensuring operational funding for the next 12 months[19]. - The financial statements of the company comply with the requirements of the "Enterprise Accounting Standards," reflecting the financial position as of December 31, 2025, and the operating results and cash flows for the year 2025[22]. Inventory and Fixed Assets - Inventory is classified into categories such as raw materials, work in progress, and finished goods, with costs including purchase costs and processing costs[76]. - The company uses a perpetual inventory system for inventory tracking[78]. - Fixed assets are recognized when they are held for production, service provision, leasing, or management, and have a useful life exceeding one accounting year[94]. - The company uses the straight-line method for depreciation of fixed assets, with a depreciation rate of 3.23% for buildings and 5.39% to 16.17% for machinery and equipment[97]. Taxation - The company has a corporate income tax rate of 15% for enterprises in encouraged industries located in the western region, effective from January 1, 2021, to December 31, 2030[163]. - The company recognizes deferred tax assets related to temporary differences and tax losses when it is probable that sufficient taxable income will be available[158]. Lease Accounting - The company recognizes right-of-use assets for leases, excluding short-term leases and low-value asset leases, and depreciates these assets using the straight-line method[143]. - Initial measurement of lease liabilities includes the present value of unpaid lease payments, adjusted for any lease incentives received[144]. Financial Instruments - Financial instruments are recognized when the company becomes a party to a financial asset, financial liability, or equity instrument[45]. - The company classifies financial assets at initial recognition into three categories: measured at amortized cost, measured at fair value with changes recognized in other comprehensive income, and measured at fair value with changes recognized in profit or loss[46].